<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00846456</url>
  </required_header>
  <id_info>
    <org_study_id>DC-CAST-GBM</org_study_id>
    <nct_id>NCT00846456</nct_id>
  </id_info>
  <brief_title>Safe Study of Dendritic Cell (DC) Based Therapy Targeting Tumor Stem Cells in Glioblastoma</brief_title>
  <official_title>Phase I/II Trial of Vaccine Therapy With Tumor Stem Cell Derived mRNA- Transfected Dendritic Cells in Patients Receiving Standard Therapy for Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study induces an immune response towards the stem-cell like part of glioblastomas in&#xD;
      combination with standard therapy. The aim is to define and characterize the feasibility,&#xD;
      potential adverse effects of such therapy and measure time to progression and survival.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>During follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of immunological response, time to disease progression and survival time</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">20</enrollment>
  <condition>Glioblastoma</condition>
  <condition>Brain Tumor</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Dendritic cell vaccine with mRNA from tumor stem cells</intervention_name>
    <description>Intradermal injection of transfected dendritic cells</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Accessible volume and quality of tumor tissue for vaccine production&#xD;
&#xD;
          -  MRI after surgery with minimal tumor remnant.&#xD;
&#xD;
          -  Between 18 and 70 years of age.&#xD;
&#xD;
          -  Must have histologically confirmed glioma grade IV, and a candidate for combined&#xD;
             radiation therapy and chemotherapy (&quot;Stupps regimen&quot;).&#xD;
&#xD;
          -  Must be ambulatory with a ECOG performance status 0 or 1.&#xD;
&#xD;
          -  A minimum 4 weeks must have elapsed between the end of glucocorticoid treatment and&#xD;
             beginning of vaccination.&#xD;
&#xD;
          -  Signed informed consent and expected cooperation of the patients for the treatment and&#xD;
             follow up must be obtained and documented.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Tumor in a localization where a modest increase in size due to reactive oedema may&#xD;
             have a large impact on patients neurological condition.&#xD;
&#xD;
          -  Large tumor remnant after surgery.&#xD;
&#xD;
          -  History of prior malignancy other than glioma, with the exception of curatively&#xD;
             treated basal cell or squamous cell carcinoma of the skin and ca. cervicis stage IB.&#xD;
&#xD;
          -  Chronic active infection requiring antibiotic therapy.&#xD;
&#xD;
          -  Significant cardiac or other medical illness that would limit activity or survival,&#xD;
             such as severe congestive heart failure, unstable angina, or serious cardiac&#xD;
             arrhythmia.&#xD;
&#xD;
          -  Prior splenectomy.&#xD;
&#xD;
          -  Glucocorticoid treatment not possible to terminate due to autoimmune disease or&#xD;
             increased intracranial pressure.&#xD;
&#xD;
          -  Adverse reactions to vaccines such as asthma, anaphylaxis or other serious reactions.&#xD;
&#xD;
          -  History of immunodeficiency or autoimmune disease such as rheumatoid arthritis,&#xD;
             systemic lupus erythematosus, scleroderma, polymyositis- dermatomyositis, juvenile&#xD;
             onset insulin dependent diabetes, or a vasculitic syndrome.&#xD;
&#xD;
          -  Chemotherapy or other potentially immune-suppressive therapy that has been&#xD;
             administered within 4 weeks prior to vaccination.&#xD;
&#xD;
          -  Pregnancy or lactation.&#xD;
&#xD;
          -  Any reason why, in the opinion of the investigator, the patient should not&#xD;
             participate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steinar Aamdal, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Cancer Research, Rikshospitalet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Iver A Langmoen, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Dept of Neurosurgery, Ulleval University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gunnar Kvalheim, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Dept of cellular therapy, Rikshospitalet HF</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gustav Gaudernack, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Inst. of Immunotherapy, Rikshospitalet HF</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Knut Lote, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Dept. of oncology, Rikshospitalet HF</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jon Berg-Johnsen, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Dept. of Neurosurgery, Rikshospitalet HF</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carl Langberg, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Dept of oncology, Ulleval University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marta Nyakas, MD</last_name>
    <role>Study Director</role>
    <affiliation>Dept. of Clinical Cancer Research, Rikshospitalet HF</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Einar O Vik-Mo, MD</last_name>
    <role>Study Director</role>
    <affiliation>Dept of Neurosurgery, Ulleval University Hospital</affiliation>
  </overall_official>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>February 15, 2009</study_first_submitted>
  <study_first_submitted_qc>February 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2009</study_first_posted>
  <last_update_submitted>October 19, 2015</last_update_submitted>
  <last_update_submitted_qc>October 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Steinar Aamdal</investigator_full_name>
    <investigator_title>Steinar Aamdal</investigator_title>
  </responsible_party>
  <keyword>Tumor setm cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

